BOYDSense is a medical device company developing a non-invasive platform for monitoring chronic diseases, with an initial focus on diabetes. The company's flagship product is a breath analysis device that measures blood glucose concentrations without the need for finger pricking or other invasive methods. This innovative technology aims to drastically improve the way patients with diabetes monitor their glucose levels, facilitating a gentler and more convenient approach to disease management.
BOYDSense's breath glucose monitoring platform operates by analyzing specific biomarkers present in a person's exhaled breath, which correlate with their blood glucose levels. This non-invasive method eliminates the discomfort and hassle associated with traditional blood glucose testing, potentially improving adherence and quality of life for diabetic patients.
In 2023, BOYDSense completed a clinical study in partnership with Toulouse University Hospital, validating the potential of its breath analysis technology. The company has also made progress in miniaturizing its device for enhanced portability and user-friendliness.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.